These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 36924100)
1. Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study. Yu N; Cheng G; Li J; Liang J; Zhang T; Deng L; Liu W; Wang J; Zhai Y; Wang W; Xiao Z; Zhou Z; Chen D; Feng Q; Bi N; Wang X Curr Cancer Drug Targets; 2023; 23(8):653-662. PubMed ID: 36924100 [TBL] [Abstract][Full Text] [Related]
2. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial. Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy analysis of chemoradiotherapy/radiotherapy combined with nimotuzumab for treating unresectable oesophageal squamous cell carcinoma in elderly patients: a retrospective analysis. Zhang Y; Wang J; Cui D; Kong L; Wang P; Fu Z; Su M; Li B; Liang J BMC Gastroenterol; 2022 Dec; 22(1):526. PubMed ID: 36528571 [TBL] [Abstract][Full Text] [Related]
4. TENERGY: multicenter phase II study of Atezolizumab monotherapy following definitive Chemoradiotherapy with 5-FU plus Cisplatin in patients with unresectable locally advanced esophageal squamous cell carcinoma. Bando H; Kotani D; Tsushima T; Hara H; Kadowaki S; Kato K; Chin K; Yamaguchi K; Kageyama SI; Hojo H; Nakamura M; Tachibana H; Wakabayashi M; Fukutani M; Togashi Y; Fuse N; Nishikawa H; Kojima T BMC Cancer; 2020 Apr; 20(1):336. PubMed ID: 32312286 [TBL] [Abstract][Full Text] [Related]
5. Comparison of concurrent chemoradiotherapy with radiotherapy alone for locally advanced esophageal squamous cell cancer in elderly patients: A randomized, multicenter, phase II clinical trial. Liu Y; Zheng Z; Li M; Zhang Y; Zhao F; Gong H; Lin H; Huang W; Chen X; Xu Z; Li X; Liu W; Cui Y; Zheng A; Li B Int J Cancer; 2022 Aug; 151(4):607-615. PubMed ID: 35419831 [TBL] [Abstract][Full Text] [Related]
6. Combined nimotuzumab with chemoradiotherapy in patients with locally advanced or metastatic esophageal squamous cell carcinoma: A retrospective study. Lai X; Gu Q; Zheng X; Liu G; Feng W; Lin X; Mao W J Cancer Res Ther; 2016 Oct; 12(Supplement):89-95. PubMed ID: 27721263 [TBL] [Abstract][Full Text] [Related]
7. Benefit of chemotherapy based on platinum with definitive radiotherapy in older patients with locally advanced esophageal squamous cell carcinoma. Wu H; Yu Y; Zheng Q; Liu T; Wu Y; Wang Z; Zheng H; Liu L; Li J Radiat Oncol; 2021 Oct; 16(1):207. PubMed ID: 34717670 [TBL] [Abstract][Full Text] [Related]
8. Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study. Lian HM; Wu JL; Liufu WJ; Yu TT; Niu SQ; Bao Y; Peng F Cancer Immunol Immunother; 2024 Feb; 73(3):55. PubMed ID: 38366287 [TBL] [Abstract][Full Text] [Related]
9. The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study. Hu J; Chen Z; Lv J; Zheng Z; Bei Y; Chen X; Zheng L; Song W; Xu Y Front Oncol; 2022; 12():905422. PubMed ID: 35898885 [TBL] [Abstract][Full Text] [Related]
10. Radiotherapy with S-1 for the treatment of esophageal squamous cell carcinoma 75 years or older. Gu D; Wang T; Guo Y; Liu Y; Fang Y; Chen W; Wang Q; Zhang R; Shi H; Wu D; Zhang Z; Zhou G; Ye J Radiat Oncol; 2024 Aug; 19(1):112. PubMed ID: 39210445 [TBL] [Abstract][Full Text] [Related]
11. Overall Survival of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Nimotuzumab in the Real World. Saumell Y; Sanchez L; González S; Ortiz R; Medina E; Galán Y; Lage A Adv Ther; 2017 Dec; 34(12):2638-2647. PubMed ID: 29134427 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial. Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552 [TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study. Feng G; Li J; Yu N; Zheng Z; Yang X; Deng L; Zhang T; Wang W; Liu W; Wang J; Feng Q; Lyu J; Xiao Z; Zhou Z; Bi N; Qin J; Wang X Chin J Cancer Res; 2024 Jun; 36(3):270-281. PubMed ID: 38988486 [TBL] [Abstract][Full Text] [Related]
14. Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma. Zhou XL; Yu CH; Wang WW; Ji FZ; Xiong YZ; Zhu WG; Tong YS Radiat Oncol; 2021 May; 16(1):94. PubMed ID: 34039375 [TBL] [Abstract][Full Text] [Related]
15. Comparison of definitive chemoradiotherapy and radiotherapy alone in patients older than 75 years with locally advanced esophageal carcinoma: A retrospective cohort study. Zhao Q; Hu G; Xiao W; Chen Y; Shen M; Tang Q; Ning X Medicine (Baltimore); 2017 Sep; 96(35):e7920. PubMed ID: 28858114 [TBL] [Abstract][Full Text] [Related]
16. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma. Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097 [TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficiency of concurrent chemoradiotherapy with a single agent or double agents vs radiotherapy alone for elderly patients with esophageal squamous cell carcinoma: Experience of two centers. Huang C; Zhu Y; Li Q; Zhang W; Liu H; Zhang W; Hu Y; Yuan Y; Liu M Cancer Med; 2019 Jan; 8(1):28-39. PubMed ID: 30600600 [TBL] [Abstract][Full Text] [Related]
18. Paclitaxel and cisplatin combined with concurrent involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: a phase II clinical trial. Li H; Fang Y; Gu D; Du M; Zhang Z; Sun L; Zhou G; Ye J Radiat Oncol; 2022 Jun; 17(1):105. PubMed ID: 35681233 [TBL] [Abstract][Full Text] [Related]
19. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study. Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B Front Immunol; 2023; 14():1193394. PubMed ID: 37325650 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with or without nimotuzumab in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study. Yang Z; Zuo Q; Liu R; Wu H; Xiong L; Jia J; Xiang Z BMC Cancer; 2023 Nov; 23(1):1140. PubMed ID: 37996813 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]